Atherosclerosis remains the underlying cause of the majority of cardiovascular diseases contributing to mortality. Our overall hypothesis is that pathological activation of two blood contact system proteins, factor (F) XI and FXII, mediate platelet-endothelial interactions to promote inflammation and leukocyte trafficking in experimental models of atherosclerotic plaque formation. Our preliminary studies linking contact activation to inflammation and platelet activation suggest that pharmacological targeting of FXI could reduce vascular inflammation, atherogenesis, and its cardiovascular complications, and would be safer than traditional anticoagulants or platelet inhibitors, which carry a significant risk of fatal bleeding. Our work and findings to date have opened the window towards the development of safer antithrombotic strategies. This program will take a new direction to study whether contact activation increases platelet- endothelial cell interactions, leukocyte recruitment and infiltration, and inflammation to promote atherosclerotic plaque formation. This program will build on our ability to develop tools for molecular imaging of cell interactions, the creation of novel inhibitors of contact activation, and rational and responsible use of and translation from in vitro studies to in vivo mouse and non-human primate models of disease.
In Aim 1 we will determine the role of FXI in activating platelets to promote atherogenesis. We will test our hypothesis that FXI-dependent platelet activation promotes recruitment of leukocytes to inflamed endothelium.
In Aim 2 we will determine the role of FXII in promoting inflammation in atherogenesis. We will test our hypothesis that FXII activation of and by FXI induces cytokine and complement generation that contribute to inflammation to promote atherogenesis. We will translate our mechanistic in vitro studies to define the pathological role of contact activation in 2 distinct animal models of atherogenesis. The translational relevance of our project will be the potential identification of safe molecular targets and mechanisms that could support the development of novel pharmacological approaches to address the problem of progressive atherosclerosis.

Public Health Relevance

Our work has pioneered efforts to establish the blood proteins factor XI and XII as novel drug targets to prevent or treat blood clots and reduce inflammation, with limited or no risk of treatment-associated bleeding. Arteriosclerosis narrows arterial blood vessels and can induce blood clots that cause stroke and heart attack and has been associated with chronic blood vessel inflammation, while inherited factor XI deficiency reduces cardiovascular events. We propose that factors XI and XII may be complicit in cardiovascular disease that remains the leading cause of mortality in the country. This project will evaluate whether and how these two proteins contribute to experimental atherosclerosis and inflammation, and determine whether pharmacological inhibition of factors XI or XII could have the potential to slow the progression of atherosclerosis-associated ischemic cardiovascular diseases.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL101972-11
Application #
9928074
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Warren, Ronald Q
Project Start
2010-07-15
Project End
2023-03-31
Budget Start
2020-04-01
Budget End
2021-03-31
Support Year
11
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Other Basic Sciences
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Healy, Laura D; Rigg, Rachel A; Griffin, John H et al. (2018) Regulation of immune cell signaling by activated protein C. J Leukoc Biol :
Rigg, Rachel A; Healy, Laura D; Chu, Tiffany T et al. (2018) Protease-activated receptor 4 activity promotes platelet granule release and platelet-leukocyte interactions. Platelets :1-10
Mitrugno, Annachiara; Sylman, Joanna L; Rigg, Rachel A et al. (2018) Carpe low-dose aspirin: the new anti-cancer face of an old anti-platelet drug. Platelets 29:773-778
Tillman, Benjamin F; Gruber, Andras; McCarty, Owen J T et al. (2018) Plasma contact factors as therapeutic targets. Blood Rev 32:433-448
Zilberman-Rudenko, Jevgenia; Reitsma, Stéphanie E; Puy, Cristina et al. (2018) Factor XII Activation Promotes Platelet Consumption in the Presence of Bacterial-Type Long-Chain Polyphosphate In Vitro and In Vivo. Arterioscler Thromb Vasc Biol 38:1748-1760
Ngo, Anh T P; McCarty, Owen J T; Aslan, Joseph E (2018) TRPing out Platelet Calcium: TRPM7 (Transient Receptor Potential Melastatin-Like 7) Modulates Calcium Mobilization and Platelet Function via Phospholipase C Interactions. Arterioscler Thromb Vasc Biol 38:285-286
Rocheleau, Anne D; Khader, Ayesha; Ngo, Anh T P et al. (2018) Pilot study of novel lab methodology and testing of platelet function in adolescent women with heavy menstrual bleeding. Pediatr Res 83:693-701
Zilberman-Rudenko, Jevgenia; Zhao, Frank Z; Reitsma, Stephanie E et al. (2018) Effect of Pneumatic Tubing System Transport on Platelet Apheresis Units. Cardiovasc Eng Technol 9:515-527
Mitrugno, Annachiara; Rigg, Rachel A; Laschober, Nicole B et al. (2018) Potentiation of TRAP-6-induced platelet dense granule release by blockade of P2Y12 signaling with MRS2395. Platelets 29:383-394
Sylman, Joanna L; Boyce, Hunter B; Mitrugno, Annachiara et al. (2018) A Temporal Examination of Platelet Counts as a Predictor of Prognosis in Lung, Prostate, and Colon Cancer Patients. Sci Rep 8:6564

Showing the most recent 10 out of 82 publications